Cryoablation Or Brachytherapy? Endocare Promotes Prostate First-Line Option
This article was originally published in The Gray Sheet
Endocare is hoping that the results of an eight-year 590-patient registry study will convince more urologists to use cryoablation as an alternative to brachytherapy for first-line treatment of prostate cancer
You may also be interested in...
Endocare's Feb. 21 acquisition of Timm Medical Technolgies provides a much-enlarged customer base for its urology product offering
Minimally-invasive cryosurgical system gains 510(k) clearance for "keyhole" thoracoscopic cardiac tissue ablation procedures to treat arrhythmias. The clearance opens the door for "a new generation of devices currently under development that treat certain cardiac conditions in a less invasive fashion" under a September 2001 strategic alliance with CryoCath Technologies (1"The Gray Sheet" Oct. 1, 2001, p. 30)...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.